Bounce Breaks — GSK Strikes $10.6B

Rundown · 2026-06-10

Chip bounce fails: Nasdaq -0.97% as the tech rebound stalls Day 2; Dow eked out +0.17% to 50,872.11; GSK buying Nuvalent for $10.6B at a 40% premium — CPI today.

Market Performance

• S&P 500: 7,386.65 (-0.26%) — chip rebound failed; index drifted lower into the close
• Nasdaq: 25,678.82 (-0.97%) — tech weakness resumed; SMH -1% after Monday's +6%
• Dow: 50,872.11 (+0.17%) — +86 points; the only major in green on defensive rotation
• Russell 2000: mixed; small caps still consolidating after last week's -3.47%
• Sector leaders: Health Care (NUVL deal), Cons. Staples · Laggards: Tech, Comm Services
• 10Y yield: 4.52% — down ~3 bps; bond market starting to fade higher-for-longer
• WTI crude: below $90 — Hormuz agreement optimism; first sub-$90 close in weeks
• DXY: softer · Gold: modestly higher — the oil drop is helping the disinflation case
• Trump: "final throes" of an Iran deal, but Israel renewed its assault on Lebanon — downside risk back

CPI Today: 4.2% Headline / 2.9% Core Sets the Whole Tape

• Consensus headline: +4.2% YoY — up from 3.8% in April; energy still in the pipeline
• Core consensus: +2.9% — slight tick up from 2.8%; sticky services the key watch item
• 10Y at 4.52% going into the print — bond market braced after Friday's NFP shock
• Hot print cements higher-for-longer + revives the hike trade ahead of Warsh's debut FOMC
• Cool surprise relieves duration pressure and lets the chip bounce restart
• WTI below $90 is the first real disinflation tailwind in 8 weeks

GSK + Nuvalent: $10.6B Oncology Deal Anchors an M&A Wave

• GSK acquiring NUVL for $10.6B all-cash at $124/share — ~40% premium
• NUVL is a late-stage oncology biotech focused on lung-cancer subsets with specific mutations
• Helps GSK offset an anticipated revenue decline when its HIV franchise loses exclusivity in 2028
• NUVL +39% intraday on the news; oncology M&A premiums are back to 2021 levels
• J&J also bought protein-degrader biotech Firefly Bio for $1B — biotech consolidation accelerating
• ADP labor: private employers averaging +29K/week — modest but consistent with a stable 4.3% UE

Notable Movers

• (DKNG) +11% — an SEC filing revealed Predictions hit $1.3B annualized consumer volume in May, +24% MoM
• (SJM) +10% — beat quarterly estimates; Hostess + Uncrustables drove the upside
• (SAIL) -11% — Q2 guide implied ARR growth decelerating to ~24% from 26%; revenue growth to ~17-18%

Private Dealmaking

• Nuvalent (oncology · GSK acq.) — $10.6B
• Iceye (satellites · Finland) — ~$1.1B
• Firefly Bio (protein degraders · J&J acq.) — $1B
• Kneat (digital validation · Thoma Bravo acq.) — ~$470M
• NinjaOne (IT management) — $400M
• Beacon (AI holdco) — $225M

TLDR

• S&P -0.26% to 7,386.65, Nasdaq -0.97% — chip bounce failed Day 2; Dow +0.17% held green
• GSK buying NUVL for $10.6B at a 40% premium; NUVL +39% intraday — biotech M&A back
• CPI today consensus 4.2% headline / 2.9% core — the print resets the rate path
• 10Y down to 4.52%; WTI below $90 for the first time in weeks on Hormuz progress
• DKNG +11% (Predictions at $1.3B annualized); SAIL -11% on an ARR deceleration guide
• Israel renewed its Lebanon assault hours after Trump's "final throes" comment — geopolitical risk back

The Bottom Line

The bounce already broke. Chips couldn't hold Monday's relief and CPI is the gate that decides whether last week's rout was the start or the whole correction. Headline +4.2% / core +2.9% is hot but already priced — the trade is what surprises. A cool print plus oil below $90 could trigger a real reversal. A hot print into Israel's Lebanon escalation puts the 30Y back above 5.10% and Warsh walks into his first FOMC with no room to maneuver.

_For informational purposes only. Not investment advice._